COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer

Gulyas Miklos; Mattsson Johanna Sofia Margareta; Lindgren Andrea; Ek Lars; Lundstrom Kristina Lamberg; Behndig Annelie; Holmberg Erik; Micke Patrick; Bergman Bengt

首页> 外文期刊>Acta oncologica. >COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer

【24h】

COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer

机译：COX-2除了晚期非小细胞肺癌中的标准化疗之外的COX-2表达和效果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to demonstrate a benefit of adding COX-2 inhibitors to standard chemotherapy. The aim of this study was to analyze COX-2 expression in tumor and stromal cells as predictive biomarker for COX-2 inhibition.

机译：目的：在几种癌症类型中提出抑制环氧化酶-2（COX-2）作为治疗选择。然而，在非小细胞肺癌（NSCLC）中，III期试验未能证明将COX-2抑制剂添加到标准化疗的益处。本研究的目的是将肿瘤和基质细胞中的COX-2表达分析为用于COX-2抑制的预测生物标志物。

著录项

来源
《Acta oncologica.》 |2018年第2期|共7页
作者
Gulyas Miklos; Mattsson Johanna Sofia Margareta; Lindgren Andrea; Ek Lars; Lundstrom Kristina Lamberg; Behndig Annelie; Holmberg Erik; Micke Patrick; Bergman Bengt;
展开▼
作者单位

Uppsala Univ Dept Immunol Genet &

Pathol Uppsala Sweden;

Uppsala Univ Dept Immunol Genet &

Pathol Uppsala Sweden;

Linkoping Univ Dept Clin &

Expt Med Allergy Ctr Fac Hlth Sci Linkoping Sweden;

Skane Univ Hosp Pulm Med Lund Sweden;

Akad Hosp Pulm Med Uppsala Sweden;

Norrland Univ Hosp Pulm Med Umea Sweden;

Univ Gothenburg Sahlgrenska Acad Inst Clin Sci Dept Oncol Gothenburg Sweden;

Uppsala Univ Dept Immunol Genet &

Pathol Uppsala Sweden;

Univ Gothenburg Sahlgrenska Acad Inst Med Dept Resp Med Gothenburg Sweden;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer [J] . Gulyas Miklos, Mattsson Johanna Sofia Margareta, Lindgren Andrea, Acta oncologica. . 2018,第2期

机译：COX-2除了晚期非小细胞肺癌中的标准化疗之外的COX-2表达和效果
2. Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX-2 Overexpression: CALGB 30801 (Alliance) [J] . Edelman M. J., Wang X., Hodgson L., International Journal of Radiation Oncology, Biology, Physics . 2017,第1期

机译：Celecoxib（c）的第3阶段试验的最终结果除了具有COX-2过表达的先进非小细胞肺癌的标准化疗：Calgb 30801（联盟）
3. Baseline Urinary PGE-M Is a Prognostic and Predictive Marker for Cox-2 Inhibition in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): CALGB 30801 (Alliance) [J] . Edelman M. J., Wang X., Hodgson L., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：基线尿液PGE-M是除晚期非小细胞肺癌（NSCLC）的标准化学疗法外的Cox-2抑制的预后和预测标志物：CALGB 30801（联盟）
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. Phase III Randomized Placebo-Controlled Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance) [O] . Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, -1

机译：塞来昔布的III期随机安慰剂对照双盲试验以及标准化疗方案用于晚期非小细胞肺癌加环氧合酶-2过表达的标准化疗：CALGB 30801（联盟）
7. COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer [O] . Miklos Gulyas, Johanna Sofia Margareta Mattsson, Andrea Lindgren, 2017

机译：CEX-2 Celecoxib的表达和效果除了晚期非小细胞肺癌中的标准化疗外

COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅